[HTML][HTML] Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
Molecular psychiatry, 2017 - nature.com
This study was designed to test the interaction between amyloid-β and tau proteins as a
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.
TA Pascoal, S Mathotaarachchi, S Mohades… - Molecular …, 2016 - europepmc.org
This study was designed to test the interaction between amyloid-β and tau proteins as a
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
[引用][C] Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
S GAUTHIER - Molecular Psychiatry, 2016 - reflexion.hec.ca
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical
Alzheimer's disease - GAUTHIER, Serge en Rechercher Bienvenue Revues HEC Montréal À …
Alzheimer's disease - GAUTHIER, Serge en Rechercher Bienvenue Revues HEC Montréal À …
Amyloid-[beta] and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
TA Pascoal, S Mathotaarachchi, S Mohades… - Molecular …, 2017 - go.gale.com
This study was designed to test the interaction between amyloid-[beta] and tau proteins as a
determinant of metabolic decline in preclinical Alzheimer% apos; s disease (AD). We …
determinant of metabolic decline in preclinical Alzheimer% apos; s disease (AD). We …
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
TA Pascoal, S Mathotaarachchi… - Molecular …, 2017 - pubmed.ncbi.nlm.nih.gov
This study was designed to test the interaction between amyloid-β and tau proteins as a
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
[HTML][HTML] Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
TA Pascoal, S Mathotaarachchi, S Mohades… - Molecular …, 2017 - ncbi.nlm.nih.gov
This study was designed to test the interaction between amyloid-β and tau proteins as a
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
determinant of metabolic decline in preclinical Alzheimer's disease (AD). We assessed 120 …
[PDF][PDF] Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
Molecular Psychiatry, 2016 - researchgate.net
AlzheimerLs disease (AD) clinically develops in the context of presymptomatic, mild
cognitive impairment and dementia stages, and can be quantified in vivo via imaging and …
cognitive impairment and dementia stages, and can be quantified in vivo via imaging and …
[HTML][HTML] Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
TA Pascoal, S Mathotaarachchi, S Mohades… - Molecular …, 2017 - ncbi.nlm.nih.gov
This study was designed to test the interaction between amyloid-β and tau proteins as a
determinant of metabolic decline in preclinical Alzheimer's disease. We assessed 120 …
determinant of metabolic decline in preclinical Alzheimer's disease. We assessed 120 …
Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.
TA Pascoal, S Mathotaarachchi, S Mohades… - Molecular …, 2016 - europepmc.org
This study was designed to test the interaction between amyloid-β and tau proteins as a
determinant of metabolic decline in preclinical Alzheimer's disease. We assessed 120 …
determinant of metabolic decline in preclinical Alzheimer's disease. We assessed 120 …